Beijing News (Reporter Wang Kara) On December 13, the National Health Insurance Administration announced the results of the adjustment of the 2023 National Medical Insurance Drug Catalog, and a total of 126 new drugs entered the medical insurance. Among them, Fosun Pharma's three domestic new drugs have been included in the new version of the National Medical Insurance Drug List, including Keprasheng Hydrochloride Tablets (Beiwen), Toperifilgrastim Injection (Peijin), and Sacubitril Valsartan Sodium Tablets (Yixintan).
Kepra Hydrochloride Tablets is the first potassium competitive acid blocker (P-CAB) independently developed in China, and the first P-CAB approved for the dual indications of reflux esophagitis (RE) and duodenal ulcer (DUs) in China, which belongs to the first class of innovative drugs of chemical drugs. In the phase III study, the mucosal healing rate of 8 weeks in reflux esophagitis was 958%, * duodenal ulcer has an ulcer healing rate of 94 at 6 weeks4%。
Toperi filgrastim injection is a long-acting recombinant human granulocyte-stimulating factor product independently developed by China with independent intellectual property rights, and it is also a first-class innovative drug for biological products certified by the "Eleventh Five-Year Plan" National Science and Technology Major Project. It adopts a new PEG structure, has a longer half-life and a lower dose of administration, which not only reduces the risk of bone marrow hyperstimulation, but also reduces the incidence of bone pain. At the same time, the molecular weight of toperfilgrastim increases, retains the bioactive mass to a greater extent, and promotes neutrophil production stronger.
Yixintan (sacubitril-valsartan sodium tablets) is a first-line drug for heart failure and hypertension with independent intellectual property rights and innovative crystal form. The results of the study showed that sacubitril-valsartan sodium tablets could further reduce the composite endpoint of cardiovascular death or hospitalization for heart failure by 20% and the risk of rehospitalization of heart failure by 21% in patients with heart failure with reduced ejection fraction. Compared with the traditional five classes of antihypertensive drugs, the antihypertensive mechanism of the drug is more advanced, and it can comprehensively act on multiple targets such as vasodilation, sodium excretion diuresis, RaaS inhibition and sympathetic nerve inhibition, and can not only inhibit the antihypertensor system, but also enhance the antihypertensive system, and exert a 1+1 2 antihypertensive effect and stronger target organ protection.
Proofreading by Yang Xuli.